Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
109 studies found for:    "Fabry disease"
Show Display Options
Rank Status Study
21 Withdrawn Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease
Conditions: Fabry Disease;   Neuropathic Pain
Interventions: Drug: Gabapentin;   Drug: placebo
22 Completed Replagal Enzyme Replacement Therapy for Adults With Fabry Disease
Condition: Fabry Disease
Interventions: Drug: Replagal (Agalsidase Alfa);   Drug: Replagal
23 Completed Alternative Dosing and Regimen of Replagal to Treat Fabry Disease
Condition: Fabry Disease
Intervention: Drug: Replagal
24 Completed Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity
Condition: Fabry Disease
Intervention:
25 Active, not recruiting Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta
Condition: Fabry Disease
Intervention:
26 Completed An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: Replagal
27 Completed Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: AT1001
28 Completed
Has Results
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: Agalsidase alfa
29 Recruiting Physician Initiated Request for Migalastat in Individual Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: migalastat HCl
30 Active, not recruiting Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: migalastat HCl 150 mg
31 Completed Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study
Condition: Fabry Disease
Intervention: Drug: AT1001
32 Completed
Has Results
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease
Condition: Fabry Disease
Intervention: Drug: Agalsidase beta
33 Recruiting Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Biological: Lentivirus Alpha-gal A transduced stem cells
34 Completed Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride;   Biological: agalsidase
35 Unknown  Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers
Conditions: Fabry Disease, Cardiac Variant;   Right Ventricular Hypertrophy
Intervention:
36 Completed Anderson-Fabry Disease in Chronic Kidney Disease Patients Not on Renal Replacement Therapy
Condition: Focus of Study: Prevalence of Fabry Disease in CKD Population
Intervention:
37 Enrolling by invitation Fabry's Disease and Pregnancy (PREFAB)
Conditions: Fabry's Disease;   Pregnancy
Intervention: Other: Questionnaire
38 Recruiting Fabry Disease in Cerebrovascular Disease
Condition: Fabry Disease
Intervention: Genetic: 26 common Fabry mutation types in Taiwan
39 Completed Neuropathic Pain and Fabry Disease
Condition: Fabry Disease
Intervention:
40 Completed Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains
Conditions: Pain;   Fabry's Disease
Intervention: Genetic: Blood sampling for biological and genetic analysis

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years